Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 980 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) CEO Kyle Gano sold 980 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $118.39, for a total transaction of $116,022.20. Following the transaction, the chief executive officer now directly owns 137,658 shares in the company, valued at $16,297,330.62. The trade was a 0.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kyle Gano also recently made the following trade(s):

• On Friday, January 31st, Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.87, for a total transaction of $235,572.67.
• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock traded down $1.85 on Friday, reaching $115.02. 1,479,784 shares of the company's stock were exchanged, compared to its average volume of 952,604. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The firm's 50-day moving average is $137.83 and its two-hundred day moving average is $130.54. The company has a market capitalization of $11.65 billion, a P/E ratio of 34.96 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. On average, analysts expect that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

Large investors have recently modified their holdings of the business. Caprock Group LLC purchased a new position in Neurocrine Biosciences in the 4th quarter worth approximately $236,000. Plato Investment Management Ltd boosted its stake in shares of Neurocrine Biosciences by 2,481.9% in the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company's stock worth $1,263,000 after acquiring an additional 10,548 shares during the period. Swiss National Bank boosted its stake in Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company's stock valued at $34,416,000 after buying an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $3,236,000. Finally, KBC Group NV increased its holdings in Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company's stock worth $2,186,000 after purchasing an additional 8,332 shares during the period. Institutional investors own 92.59% of the company's stock.

Wall Street Analyst Weigh In

NBIX has been the topic of several research analyst reports. Guggenheim dropped their target price on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a report on Monday, February 10th. Royal Bank of Canada dropped their target price on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a report on Friday, February 7th. Piper Sandler restated an "overweight" rating and set a $160.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Morgan Stanley raised their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 target price for the company. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $166.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.